Online access FREE through June 2009. Click Here.
Current Issue
(coming in Jan 2009)
Click here to see full image, courtesy of Joost M. Bakker, PhD., Sr. Scientific Writer & Graphic Designer, Genmab BV, Utrecht, The Netherlands.
Potential Authors:
Page and color charges are waived for the first 4 issues and the final version of accepted manuscripts will be posted on the web site promptly. Any content posted on the web site from now until January 2010 will always be free. Authors will receive a free print version of the issue containing their paper. For additional information on how to submit your manuscript please click here. |
Links
Mission Statement
Editorial Board
Submission Guidelines
Online Submission
Contact mAbs
Call For Papers
mAbs 101 - What are mAbs?
In January of 2009 mAbs, the first international peer-reviewed journal of its kind to focus exclusively on monoclonal antibodies, will be launched. We believe that this is an excellent time to start the journal because of the increasing focus on mAbs as therapeutics. There has been a rapid increase in mAb R&D by academia, government and industry located world wide. Novel mAb therapeutics are entering clinical study by commercial sponsors at a record pace (Figure 1) that is predicted to continue well into the future. MAbs have proven successful in the clinic (Table 1). In addition, a global market has emerged for the products - several novel mAbs not yet available in the US or EU are now approved in China.
|
|
|
|
|
Upcoming Meetings
|
- Europe's largest and most influential antibody and antibody alternative event
- Dedicated to the future development of the antibody market in Europe and beyond
- The most impressive mix of expert speakers from global pharmaceutical companies, cutting edge biotechs, research organisations and academia
- Build new relationships and future partnerships with more hours of dedicated networking than any other antibody event
|
